Skip to main content

Table 1 Effects of EVOO phenolics on breast cancer cell viability

From: Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells

  TYROSOL HYDROXYTYROSOL OLEUROPEIN AGLYCONE OLEUROPEIN GLYCOSIDE
  IC30 IC50 IC70 IC30 IC50 IC70 IC30 IC50 IC70 IC30 IC50 IC70
MCF-7 N.A. N.A. N.A. N.A. N.A. N.A. ~105 N.A. N.A. N.A. N.A. N.A.
MCF-7/HER2 N.A. N.A. N.A. N.A. N.A. N.A. 35 (95% CI = 30–40) 85 (95% CI = 82–88) N.A. N.A. N.A. N.A.
SK-Br3 ~120 N.A. N.A. ~110 N.A. N.A. 28 (95% CI = 25–31) 47 (95% CI = 43–51) 82 (95% CI = 80–84) ~110 N.A. N.A.
  1. The metabolic status of tyrosol-, hydroxytyrosol-, oleuropein aglycone-, and oleuropein glycoside-treated MCF-7, MCF-7/(pBABE)HER2 and SKBR3 breast cancer cells was evaluated using a MTT-based cell viability assay and constructing dose-response curves as described in "Methods". Inhibitory Concentrations (IC) producing the IC30, IC50 and IC70 values (the concentration of each agent needed to reduce cell viability by 30%, 50% and 70% relative to untreated control cells, respectively) were calculated by interpolation. Values are means (in μM) and 95% confidence intervals (95% CI) of three independent experiments made in triplicate.
  2. N.A. Not Available.